Cargando…

Older Age, a High Titre of Neutralising Antibodies and Therapy with Conventional DMARDs Are Associated with Protection from Breakthrough Infection in Rheumatoid Arthritis Patients after the Booster Dose of Anti-SARS-CoV-2 Vaccine

Objectives: We aimed to analyse the incidence and severity of breakthrough infections (BIs) in rheumatoid arthritis (RA) patients after a COronaVIrus Disease 2019 (COVID-19) vaccination booster dose. Methods: We enrolled 194 RA patients and 1002 healthcare workers (HCWs) as controls. Clinical, lifes...

Descripción completa

Detalles Bibliográficos
Autores principales: Picchianti-Diamanti, Andrea, Navarra, Assunta, Aiello, Alessandra, Laganà, Bruno, Cuzzi, Gilda, Salmi, Andrea, Vanini, Valentina, Maggi, Fabrizio, Meschi, Silvia, Matusali, Giulia, Notari, Stefania, Agrati, Chiara, Salemi, Simonetta, Di Rosa, Roberta, Passarini, Damiano, Di Gioia, Valeria, Sesti, Giorgio, Conti, Fabrizio, Spinelli, Francesca Romana, Corpolongo, Angela, Chimenti, Maria Sole, Ferraioli, Mario, Sebastiani, Gian Domenico, Benucci, Maurizio, Li Gobbi, Francesca, Santoro, Anna Paola, Capri, Andrea, Puro, Vincenzo, Nicastri, Emanuele, Goletti, Delia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10675674/
https://www.ncbi.nlm.nih.gov/pubmed/38006015
http://dx.doi.org/10.3390/vaccines11111684
_version_ 1785141120633667584
author Picchianti-Diamanti, Andrea
Navarra, Assunta
Aiello, Alessandra
Laganà, Bruno
Cuzzi, Gilda
Salmi, Andrea
Vanini, Valentina
Maggi, Fabrizio
Meschi, Silvia
Matusali, Giulia
Notari, Stefania
Agrati, Chiara
Salemi, Simonetta
Di Rosa, Roberta
Passarini, Damiano
Di Gioia, Valeria
Sesti, Giorgio
Conti, Fabrizio
Spinelli, Francesca Romana
Corpolongo, Angela
Chimenti, Maria Sole
Ferraioli, Mario
Sebastiani, Gian Domenico
Benucci, Maurizio
Li Gobbi, Francesca
Santoro, Anna Paola
Capri, Andrea
Puro, Vincenzo
Nicastri, Emanuele
Goletti, Delia
author_facet Picchianti-Diamanti, Andrea
Navarra, Assunta
Aiello, Alessandra
Laganà, Bruno
Cuzzi, Gilda
Salmi, Andrea
Vanini, Valentina
Maggi, Fabrizio
Meschi, Silvia
Matusali, Giulia
Notari, Stefania
Agrati, Chiara
Salemi, Simonetta
Di Rosa, Roberta
Passarini, Damiano
Di Gioia, Valeria
Sesti, Giorgio
Conti, Fabrizio
Spinelli, Francesca Romana
Corpolongo, Angela
Chimenti, Maria Sole
Ferraioli, Mario
Sebastiani, Gian Domenico
Benucci, Maurizio
Li Gobbi, Francesca
Santoro, Anna Paola
Capri, Andrea
Puro, Vincenzo
Nicastri, Emanuele
Goletti, Delia
author_sort Picchianti-Diamanti, Andrea
collection PubMed
description Objectives: We aimed to analyse the incidence and severity of breakthrough infections (BIs) in rheumatoid arthritis (RA) patients after a COronaVIrus Disease 2019 (COVID-19) vaccination booster dose. Methods: We enrolled 194 RA patients and 1002 healthcare workers (HCWs) as controls. Clinical, lifestyle and demographic factors were collected at the time of the third dose, and immunogenicity analyses were carried out in a subgroup of patients at 4–6 weeks after the third dose. Results: BIs were experienced by 42% patients (82/194) with a median time since the last vaccination of 176 days. Older age (>50 years; aHR 0.38, 95% CI: 0.20–0.74), receiving conventional synthetic disease modifying antirheumatic drugs (csDMARDs) (aHR 0.52, 95%CI: 0.30–0.90) and having a titre of neutralising antibodies >20 (aHR 0.36, 95% CI: 0.12–1.07) were identified as protective factors. Conversely, anti-IL6R treatment and anti-CD20 therapy increased BI probability. BIs were mostly pauci-symptomatic, but the hospitalisation incidence was significantly higher than in HCWs (8.5% vs. 0.19%); the main risk factor was anti-CD20 therapy. Conclusions: Being older than 50 years and receiving csDMARDs were shown to be protective factors for BI, whereas anti-IL6R or anti-CD20 therapy increased the risk. Higher neutralising antibody titres were associated with a lower probability of BI. If confirmed in a larger population, the identification of a protective cut-off would allow a personalised risk–benefit therapeutic management of RA patients.
format Online
Article
Text
id pubmed-10675674
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-106756742023-11-02 Older Age, a High Titre of Neutralising Antibodies and Therapy with Conventional DMARDs Are Associated with Protection from Breakthrough Infection in Rheumatoid Arthritis Patients after the Booster Dose of Anti-SARS-CoV-2 Vaccine Picchianti-Diamanti, Andrea Navarra, Assunta Aiello, Alessandra Laganà, Bruno Cuzzi, Gilda Salmi, Andrea Vanini, Valentina Maggi, Fabrizio Meschi, Silvia Matusali, Giulia Notari, Stefania Agrati, Chiara Salemi, Simonetta Di Rosa, Roberta Passarini, Damiano Di Gioia, Valeria Sesti, Giorgio Conti, Fabrizio Spinelli, Francesca Romana Corpolongo, Angela Chimenti, Maria Sole Ferraioli, Mario Sebastiani, Gian Domenico Benucci, Maurizio Li Gobbi, Francesca Santoro, Anna Paola Capri, Andrea Puro, Vincenzo Nicastri, Emanuele Goletti, Delia Vaccines (Basel) Article Objectives: We aimed to analyse the incidence and severity of breakthrough infections (BIs) in rheumatoid arthritis (RA) patients after a COronaVIrus Disease 2019 (COVID-19) vaccination booster dose. Methods: We enrolled 194 RA patients and 1002 healthcare workers (HCWs) as controls. Clinical, lifestyle and demographic factors were collected at the time of the third dose, and immunogenicity analyses were carried out in a subgroup of patients at 4–6 weeks after the third dose. Results: BIs were experienced by 42% patients (82/194) with a median time since the last vaccination of 176 days. Older age (>50 years; aHR 0.38, 95% CI: 0.20–0.74), receiving conventional synthetic disease modifying antirheumatic drugs (csDMARDs) (aHR 0.52, 95%CI: 0.30–0.90) and having a titre of neutralising antibodies >20 (aHR 0.36, 95% CI: 0.12–1.07) were identified as protective factors. Conversely, anti-IL6R treatment and anti-CD20 therapy increased BI probability. BIs were mostly pauci-symptomatic, but the hospitalisation incidence was significantly higher than in HCWs (8.5% vs. 0.19%); the main risk factor was anti-CD20 therapy. Conclusions: Being older than 50 years and receiving csDMARDs were shown to be protective factors for BI, whereas anti-IL6R or anti-CD20 therapy increased the risk. Higher neutralising antibody titres were associated with a lower probability of BI. If confirmed in a larger population, the identification of a protective cut-off would allow a personalised risk–benefit therapeutic management of RA patients. MDPI 2023-11-02 /pmc/articles/PMC10675674/ /pubmed/38006015 http://dx.doi.org/10.3390/vaccines11111684 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Picchianti-Diamanti, Andrea
Navarra, Assunta
Aiello, Alessandra
Laganà, Bruno
Cuzzi, Gilda
Salmi, Andrea
Vanini, Valentina
Maggi, Fabrizio
Meschi, Silvia
Matusali, Giulia
Notari, Stefania
Agrati, Chiara
Salemi, Simonetta
Di Rosa, Roberta
Passarini, Damiano
Di Gioia, Valeria
Sesti, Giorgio
Conti, Fabrizio
Spinelli, Francesca Romana
Corpolongo, Angela
Chimenti, Maria Sole
Ferraioli, Mario
Sebastiani, Gian Domenico
Benucci, Maurizio
Li Gobbi, Francesca
Santoro, Anna Paola
Capri, Andrea
Puro, Vincenzo
Nicastri, Emanuele
Goletti, Delia
Older Age, a High Titre of Neutralising Antibodies and Therapy with Conventional DMARDs Are Associated with Protection from Breakthrough Infection in Rheumatoid Arthritis Patients after the Booster Dose of Anti-SARS-CoV-2 Vaccine
title Older Age, a High Titre of Neutralising Antibodies and Therapy with Conventional DMARDs Are Associated with Protection from Breakthrough Infection in Rheumatoid Arthritis Patients after the Booster Dose of Anti-SARS-CoV-2 Vaccine
title_full Older Age, a High Titre of Neutralising Antibodies and Therapy with Conventional DMARDs Are Associated with Protection from Breakthrough Infection in Rheumatoid Arthritis Patients after the Booster Dose of Anti-SARS-CoV-2 Vaccine
title_fullStr Older Age, a High Titre of Neutralising Antibodies and Therapy with Conventional DMARDs Are Associated with Protection from Breakthrough Infection in Rheumatoid Arthritis Patients after the Booster Dose of Anti-SARS-CoV-2 Vaccine
title_full_unstemmed Older Age, a High Titre of Neutralising Antibodies and Therapy with Conventional DMARDs Are Associated with Protection from Breakthrough Infection in Rheumatoid Arthritis Patients after the Booster Dose of Anti-SARS-CoV-2 Vaccine
title_short Older Age, a High Titre of Neutralising Antibodies and Therapy with Conventional DMARDs Are Associated with Protection from Breakthrough Infection in Rheumatoid Arthritis Patients after the Booster Dose of Anti-SARS-CoV-2 Vaccine
title_sort older age, a high titre of neutralising antibodies and therapy with conventional dmards are associated with protection from breakthrough infection in rheumatoid arthritis patients after the booster dose of anti-sars-cov-2 vaccine
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10675674/
https://www.ncbi.nlm.nih.gov/pubmed/38006015
http://dx.doi.org/10.3390/vaccines11111684
work_keys_str_mv AT picchiantidiamantiandrea olderageahightitreofneutralisingantibodiesandtherapywithconventionaldmardsareassociatedwithprotectionfrombreakthroughinfectioninrheumatoidarthritispatientsaftertheboosterdoseofantisarscov2vaccine
AT navarraassunta olderageahightitreofneutralisingantibodiesandtherapywithconventionaldmardsareassociatedwithprotectionfrombreakthroughinfectioninrheumatoidarthritispatientsaftertheboosterdoseofantisarscov2vaccine
AT aielloalessandra olderageahightitreofneutralisingantibodiesandtherapywithconventionaldmardsareassociatedwithprotectionfrombreakthroughinfectioninrheumatoidarthritispatientsaftertheboosterdoseofantisarscov2vaccine
AT laganabruno olderageahightitreofneutralisingantibodiesandtherapywithconventionaldmardsareassociatedwithprotectionfrombreakthroughinfectioninrheumatoidarthritispatientsaftertheboosterdoseofantisarscov2vaccine
AT cuzzigilda olderageahightitreofneutralisingantibodiesandtherapywithconventionaldmardsareassociatedwithprotectionfrombreakthroughinfectioninrheumatoidarthritispatientsaftertheboosterdoseofantisarscov2vaccine
AT salmiandrea olderageahightitreofneutralisingantibodiesandtherapywithconventionaldmardsareassociatedwithprotectionfrombreakthroughinfectioninrheumatoidarthritispatientsaftertheboosterdoseofantisarscov2vaccine
AT vaninivalentina olderageahightitreofneutralisingantibodiesandtherapywithconventionaldmardsareassociatedwithprotectionfrombreakthroughinfectioninrheumatoidarthritispatientsaftertheboosterdoseofantisarscov2vaccine
AT maggifabrizio olderageahightitreofneutralisingantibodiesandtherapywithconventionaldmardsareassociatedwithprotectionfrombreakthroughinfectioninrheumatoidarthritispatientsaftertheboosterdoseofantisarscov2vaccine
AT meschisilvia olderageahightitreofneutralisingantibodiesandtherapywithconventionaldmardsareassociatedwithprotectionfrombreakthroughinfectioninrheumatoidarthritispatientsaftertheboosterdoseofantisarscov2vaccine
AT matusaligiulia olderageahightitreofneutralisingantibodiesandtherapywithconventionaldmardsareassociatedwithprotectionfrombreakthroughinfectioninrheumatoidarthritispatientsaftertheboosterdoseofantisarscov2vaccine
AT notaristefania olderageahightitreofneutralisingantibodiesandtherapywithconventionaldmardsareassociatedwithprotectionfrombreakthroughinfectioninrheumatoidarthritispatientsaftertheboosterdoseofantisarscov2vaccine
AT agratichiara olderageahightitreofneutralisingantibodiesandtherapywithconventionaldmardsareassociatedwithprotectionfrombreakthroughinfectioninrheumatoidarthritispatientsaftertheboosterdoseofantisarscov2vaccine
AT salemisimonetta olderageahightitreofneutralisingantibodiesandtherapywithconventionaldmardsareassociatedwithprotectionfrombreakthroughinfectioninrheumatoidarthritispatientsaftertheboosterdoseofantisarscov2vaccine
AT dirosaroberta olderageahightitreofneutralisingantibodiesandtherapywithconventionaldmardsareassociatedwithprotectionfrombreakthroughinfectioninrheumatoidarthritispatientsaftertheboosterdoseofantisarscov2vaccine
AT passarinidamiano olderageahightitreofneutralisingantibodiesandtherapywithconventionaldmardsareassociatedwithprotectionfrombreakthroughinfectioninrheumatoidarthritispatientsaftertheboosterdoseofantisarscov2vaccine
AT digioiavaleria olderageahightitreofneutralisingantibodiesandtherapywithconventionaldmardsareassociatedwithprotectionfrombreakthroughinfectioninrheumatoidarthritispatientsaftertheboosterdoseofantisarscov2vaccine
AT sestigiorgio olderageahightitreofneutralisingantibodiesandtherapywithconventionaldmardsareassociatedwithprotectionfrombreakthroughinfectioninrheumatoidarthritispatientsaftertheboosterdoseofantisarscov2vaccine
AT contifabrizio olderageahightitreofneutralisingantibodiesandtherapywithconventionaldmardsareassociatedwithprotectionfrombreakthroughinfectioninrheumatoidarthritispatientsaftertheboosterdoseofantisarscov2vaccine
AT spinellifrancescaromana olderageahightitreofneutralisingantibodiesandtherapywithconventionaldmardsareassociatedwithprotectionfrombreakthroughinfectioninrheumatoidarthritispatientsaftertheboosterdoseofantisarscov2vaccine
AT corpolongoangela olderageahightitreofneutralisingantibodiesandtherapywithconventionaldmardsareassociatedwithprotectionfrombreakthroughinfectioninrheumatoidarthritispatientsaftertheboosterdoseofantisarscov2vaccine
AT chimentimariasole olderageahightitreofneutralisingantibodiesandtherapywithconventionaldmardsareassociatedwithprotectionfrombreakthroughinfectioninrheumatoidarthritispatientsaftertheboosterdoseofantisarscov2vaccine
AT ferraiolimario olderageahightitreofneutralisingantibodiesandtherapywithconventionaldmardsareassociatedwithprotectionfrombreakthroughinfectioninrheumatoidarthritispatientsaftertheboosterdoseofantisarscov2vaccine
AT sebastianigiandomenico olderageahightitreofneutralisingantibodiesandtherapywithconventionaldmardsareassociatedwithprotectionfrombreakthroughinfectioninrheumatoidarthritispatientsaftertheboosterdoseofantisarscov2vaccine
AT benuccimaurizio olderageahightitreofneutralisingantibodiesandtherapywithconventionaldmardsareassociatedwithprotectionfrombreakthroughinfectioninrheumatoidarthritispatientsaftertheboosterdoseofantisarscov2vaccine
AT ligobbifrancesca olderageahightitreofneutralisingantibodiesandtherapywithconventionaldmardsareassociatedwithprotectionfrombreakthroughinfectioninrheumatoidarthritispatientsaftertheboosterdoseofantisarscov2vaccine
AT santoroannapaola olderageahightitreofneutralisingantibodiesandtherapywithconventionaldmardsareassociatedwithprotectionfrombreakthroughinfectioninrheumatoidarthritispatientsaftertheboosterdoseofantisarscov2vaccine
AT capriandrea olderageahightitreofneutralisingantibodiesandtherapywithconventionaldmardsareassociatedwithprotectionfrombreakthroughinfectioninrheumatoidarthritispatientsaftertheboosterdoseofantisarscov2vaccine
AT purovincenzo olderageahightitreofneutralisingantibodiesandtherapywithconventionaldmardsareassociatedwithprotectionfrombreakthroughinfectioninrheumatoidarthritispatientsaftertheboosterdoseofantisarscov2vaccine
AT nicastriemanuele olderageahightitreofneutralisingantibodiesandtherapywithconventionaldmardsareassociatedwithprotectionfrombreakthroughinfectioninrheumatoidarthritispatientsaftertheboosterdoseofantisarscov2vaccine
AT golettidelia olderageahightitreofneutralisingantibodiesandtherapywithconventionaldmardsareassociatedwithprotectionfrombreakthroughinfectioninrheumatoidarthritispatientsaftertheboosterdoseofantisarscov2vaccine